Margret Schottelius

List of Publications by Year
in descending order

84	6,139	61857	69108
papers	citations	43 h-index	77 g-index

87	87	87	5189
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	⁶⁸Ga- and ¹⁷⁷Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Journal of Nuclear Medicine, 2015, 56, 1169-1176.	2.8	432
2	¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. Journal of Nuclear Medicine, 2016, 57, 1006-1013.	2.8	432
3	Ligands for Mapping Î±_vÎ²₃-Integrin Expression in Vivo. Accounts of Chemical Research, 2009, 42, 969-980.	7.6	285
4	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. Journal of Nuclear Medicine, 2016, 57, 248-251.	2.8	201
5	99mTechnetium-based Prostate-specific Membrane Antigenâ€“radioguided Surgery in Recurrent Prostate Cancer. European Urology, 2019, 75, 659-666.	0.9	195
6	Prostate-specific Membrane Antigenâ€“radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. European Urology, 2015, 68, 530-534.	0.9	192
7	PET of CXCR4 Expression by a ⁶⁸Ga-Labeled Highly Specific Targeted Contrast Agent. Journal of Nuclear Medicine, 2011, 52, 1803-1810.	2.8	182
8	Molecular imaging targeting peptide receptors. Methods, 2009, 48, 161-177.	1.9	181
9	In vivo molecular imaging of chemokine receptor <scp>CXCR</scp> 4 expression in patients with advanced multiple myeloma. EMBO Molecular Medicine, 2015, 7, 477-487.	3.3	180
10	Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. Journal of Nuclear Medicine, 2004, 45, 892-902.	2.8	179
11	Preclinical Evaluation and First Patient Application of^{99m}Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 235-242.	2.8	170
12	Systemic Radioligand Therapy with ¹⁷⁷ Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. Journal of Urology, 2016, 196, 382-391.	0.2	166
13	Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging. Theranostics, 2015, 5, 618-630.	4.6	162
14	Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Research, 2014, 4, 63.	1.1	137
15	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 855-861.	2.8	122
16	PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Seminars in Nuclear Medicine, 2019, 49, 302-312.	2.5	120
17	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe ⁶⁸Ga-Pentixafor. Journal of Nuclear Medicine, 2015, 56, 410-416.	2.8	108
18	First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography. Clinical Cancer Research, 2004, 10, 3593-3606.	3.2	104

#	Article	IF	Citations
19	Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Engineering, Design and Selection, 2007, 20, 273-284.	1.0	104
20	Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics, 2016, 6, 849-861.	4.6	102
21	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics, 2017, 7, 1589-1597.	4.6	102
22	CXCR4-directed theranostics in oncology and inflammation. Annals of Nuclear Medicine, 2018, 32, 503-511.	1.2	98
23	Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer ⁶⁸Ga-Pentixafor for PET. Journal of Nuclear Medicine, 2017, 58, 499-506.	2.8	94
24	Improvement of Pharmacokinetics of Radioiodinated Tyr3-Octreotide by Conjugation with Carbohydrates. Bioconjugate Chemistry, 2002, 13, 1021-1030.	1.8	90
25	[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Research, 2015, 5, 68.	1.1	88
26	Value of ¹¹¹Inâ€prostateâ€specific membrane antigen (<scp>PSMA</scp>)â€radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical followâ€up. BJU International, 2017, 120, 40-47.	1.3	88
27	Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta, 2004, 92, .	0.5	85
28	[¹⁷⁷Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics, 2017, 7, 2350-2362.	4.6	84
29	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. European Urology, 2019, 76, 517-523.	0.9	81
30	Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 71-78.	2.8	76
31	Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. Theranostics, 2018, 8, 369-383.	4.6	68
32	Synthesis of Novel 1,4,7,10-Tetraazacyclodecane-1,4,7,10-Tetraacetic Acid (DOTA) Derivatives for Chemoselective Attachment to Unprotected Polyfunctionalized Compounds. Chemistry - A European Journal, 2007, 13, 6082-6090.	1.7	65
33	Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance. Journal of Nuclear Medicine, 2020, 61, 13-19.	2.8	62
34	18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1469-1474.	3.3	59
35	Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. Journal of Nuclear Medicine, 2006, 47, 566-73.	2.8	54
36	Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 28-38.	3.3	51

#	Article	IF	Citations
37	Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica, 2016, 101, 932-940.	1.7	50
38	Twins in spirit - episode I: comparative preclinical evaluation of [68Ga]DOTATATE and [68Ga]HA-DOTATATE. EJNMMI Research, 2015, 5, 22.	1.1	47
39	²¹³Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 67-73.	0.7	47
40	Chemoselective hydrazone formation between HYNIC-functionalized peptides and 18F-fluorinated aldehydes. Nuclear Medicine and Biology, 2006, 33, 173-183.	0.3	46
41	A Conformationally Frozen Peptoid Boosts CXCR4 Affinity and Antiâ€HIV Activity. Angewandte Chemie - International Edition, 2012, 51, 8110-8113.	7.2	45
42	Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, e397-e402.	0.7	45
43	Chemokine receptor â€“ Directed imaging and therapy. Methods, 2017, 130, 63-71.	1.9	45
44	Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI. Journal of Nuclear Cardiology, 2016, 23, 131-133.	1.4	44
45	Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dyeâ€“Protein Interaction. Journal of Nuclear Medicine, 2020, 61, 234-241.	2.8	42
46	New Developments in Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2019, 60, 167-171.	2.8	41
47	Development of Novel ⁶⁸Ga- and ¹⁸F-Labeled GnRH-I Analogues with High GnRHR-Targeting Efficiency. Bioconjugate Chemistry, 2008, 19, 1256-1268.	1.8	40
48	Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?. Bioconjugate Chemistry, 2020, 31, 375-395.	1.8	38
49	Modulation of Pharmacokinetics of Radioiodinated Sugar-Conjugated Somatostatin Analogues by Variation of Peptide Net Charge and Carbohydration Chemistry. Bioconjugate Chemistry, 2005, 16, 429-437.	1.8	37
50	Pharmacophoric Modifications Lead to Superpotent Î±vÎ²3 Integrin Ligands with Suppressed Î±5Î²1 Activity. Journal of Medicinal Chemistry, 2014, 57, 3410-3417.	2.9	35
51	CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma. Clinical Cancer Research, 2018, 24, 1048-1061.	3.2	34
52	Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007. EJNMMI Research, 2018, 8, 30.	1.1	33
53	A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Theranostics, 2020, 10, 8264-8280.	4.6	33
54	[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Research, 2020, 10, 45.	1.1	33

#	Article	IF	Citations
55	The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. EJNMMI Research, 2016, 6, 36.	1.1	32
56	Radiolabeled Carbohydrated Somatostatin Analogs: A Review of the Current Status. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 231-244.	0.7	31
57	Rapid and high-yield solution-phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA. Tetrahedron Letters, 2003, 44, 2393-2396.	0.7	28
58	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. Journal of Leukocyte Biology, 2021, 109, 969-989.	1.5	28
59	N-Terminal Sugar Conjugation and C-Terminal Thr-for-Thr(ol) Exchange in Radioiodinated Tyr3-octreotide:Â Effect on Cellular Ligand Trafficking in Vitro and Tumor Accumulation in Vivo. Journal of Medicinal Chemistry, 2005, 48, 2778-2789.	2.9	25
60	Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. EJNMMI Research, 2018, 8, 84.	1.1	23
61	In Vivo Targeting of CXCR4â€"New Horizons. Cancers, 2021, 13, 5920.	1.7	23
62	First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. Tomography, 2016, 2, 85-93.	0.8	22
63	Twins in spirit part II: DOTATATE and high-affinity DOTATATEâ€"the clinical experience. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1158-1165.	3.3	20
64	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e549-e552.	0.9	19
65	Preclinical evaluation of [68Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivoÂâ€"Âa comparison to [68Ga]pentixafor. EJNMMI Research, 2016, 6, 70.	1.1	18
66	[123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 45-52.	3.3	14
67	Orthogonally Protected Artificial Amino Acid as Tripod Ligand for Automated Peptide Synthesis and Labeling with [^{99m}Tc(OH₂)₃(CO)₃]⁺. Bioconjugate Chemistry, 2013, 24, 26-35.	1.8	13
68	Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo. EJNMMI Research, 2019, 9, 75.	1.1	13
69	An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides. Tetrahedron Letters, 2015, 56, 6602-6605.	0.7	10
70	[64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 2.	1.8	10
71	Click Chemistry in the Design and Production of Hybrid Tracers. ACS Omega, 2019, 4, 12438-12448.	1.6	10
72	Twins in spirit: DOTATATE and high-affinity DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1789-1789.	3.3	9

#	Article	IF	Citations
73	Effect of Carbohydration on the Theranostic Tracer PSMA I&T. ACS Omega, 2018, 3, 8278-8287.	1.6	9
74	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. Journal of Medicinal Chemistry, 2021, 64, 3449-3461.	2.9	8
75	Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 156-157.	2.8	7
76	Twins in spirit part IV â€“ [177Lu] high affinity DOTATATE. Nuklearmedizin - NuclearMedicine, 2017, 56, 1-8.	0.3	6
77	â€œLuke! Luke! Donâ€™t! Itâ€™s a trap!â€â€”spotlight on bias in animal experiments in nuclear oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1024-1026.	3.3	6
78	CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrettâ€™s esophagus. EJNMMI Research, 2022, 12, 2.	1.1	6
79	From Theranostics to Immunotheranostics: the Concept. Nuclear Medicine and Molecular Imaging, 2020, 54, 81-85.	0.6	3
80	Production of clinical radiopharmaceuticals: general pharmaceutical and radioanalytical aspects. Journal of Radioanalytical and Nuclear Chemistry, 2017, 311, 1551-1557.	0.7	2
81	The role of fluorescent and hybrid tracers in radioguided surgery in urogenital malignancies. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 261-270.	0.4	2
82	MP82-10 PSMA-RADIOGUIDED SURGERY: INTRODUCING MOLECULAR SURGERY IN PATIENTS WITH RECURRENT PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	1
83	Perspectives on translational molecular imaging and therapy: an overview of key questions to be addressed. EJNMMI Research, 2022, 12, .	1.1	1
84	Abstract 1304: AbYlinkTM: A site-selective labeling method for preclinical imaging of therapeutic antibodies. , 2021, , .		0